For the interim period of the fiscal year ending March 2027, consolidated net sales were 64,688 million yen (YoY -0.2%), operating income was 10,563 million yen (-0.9%), and interim net income was 7,263 million yen (-4.2%). Full-year forecasts remain unchanged. By segment, therapeutic devices and consumables performed steadily, while clinical laboratory testing equipment declined. The dividend forecast at the end of Q2 remains unchanged. Financial position: total assets 231,532 million yen, equity ratio 84.8%, treasury stock recorded at the equivalent of 38,847 million yen. An extraordinary general meeting of shareholders is scheduled (proposal to elect a statutory auditor, effective December 24).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6960","jir_company_name":"Fukuda Denshi Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/6960-20261030-02.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, consolidated net sales were 64,688 million yen (YoY -0.2%), operating income was 10,563 million yen (-0.9%), and interim net income was 7,263 million yen (-4.2%). Full-year forecasts remain unchanged. By segment, therapeutic devices and consumables performed steadily, while clinical laboratory testing equipment declined. The dividend forecast at the end of Q2 remains unchanged. Financial position: total assets 231,532 million yen, equity ratio 84.8%, treasury stock recorded at the equivalent of 38,847 million yen. An extraordinary general meeting of shareholders is scheduled (proposal to elect a statutory auditor, effective December 24).","jir_summary":"### Overview of Results\nFukuda Denshi Co., Ltd. posted net sales of 64,688 million yen for the interim period of the fiscal year ending March 2027, a slight decrease of 0.2% year-over-year, while ordinary income was 10,974 million yen (an increase of 0.4% YoY) and operating income was 10,563 million yen (a decrease of 0.9% YoY), representing only marginal changes. By segment, therapeutic devices maintained stable growth and consumables also saw slight increases; however, clinical laboratory testing equipment declined, affecting the overall composition. Interim net income was 7,263 million yen, down 4.2% year-over-year. Full-year forecasts remain unchanged from those announced. The financial position is sound, with total assets of 231,532 million yen and an equity ratio of 84.8%.\n\n### Shareholder and Capital Policy Developments\nThere is no change to the previously announced dividend policy. The current dividend structure assumes an ordinary dividend of 80 yen and a special dividend of 35 yen at the end of the second quarter (full-year plan unchanged). Treasury stock as of the interim period-end amounted to 10,678,419 shares, and shareholders' equity including treasury stock was 180,716 million yen. An extraordinary general meeting of shareholders is scheduled, with a proposal to elect one statutory auditor. Over the long term, maintaining robust cash flows is considered important given factors such as digital transformation in the medical device market.","jir_financial_highlights":"Net Sales: 64,688 (YoY -0.2%)\nOperating Income: 10,563 (YoY -0.9%)\nOrdinary Income: 10,974 (YoY +0.4%)\nNet Income Attributable to Owners of Parent (Interim): 7,263 (YoY -4.2%)\nTotal Assets: 231,532 (vs. prior fiscal year-end +61 hundred million yen 58 million yen)","jir_category":"","jir_hashtags":"#FukudaDenshi, #MaterialInformationFromEarnings","jir_key_figures":"Net Sales: 64,688 million yen (YoY -0.2%)\nOperating Income: 10,563 million yen (YoY -0.9%)\nInterim Net Income: 7,263 million yen (YoY -4.2%)","jir_meta_title":"Fukuda Denshi Co., Ltd. - Q2 Interim Financial Summary for FY2027 | Interim Results","jir_meta_description":"Analysis of Fukuda Denshi Co., Ltd.'s interim financial summary for FY2027: net sales 64,688 million yen, operating income 10,563 million yen, interim net income 7,263 million yen. Full-year forecast unchanged. Key segment trends and financial position summarized.","jir_og_title":"Fukuda Denshi Co., Ltd. Interim Financial Summary: Net Sales 64,688 million yen, Full-Year Forecast Unchanged","jir_og_description":"Fukuda Denshi Co., Ltd.'s interim results for FY2027: net sales 64,688 million yen, operating income 10,563 million yen, interim net income 7,263 million yen. No change to full-year forecast. Segment trends and financial condition explained.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8718,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138736","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n